CureLab Oncology, a clinical-stage biotech company, announced on Thursday that it has named Dr Aubrey C Galloway as its new chief medical officer (CMO).
In the new role, Dr Galloway will manage the clinical development strategy for the company's lead investigational compound, Elenagen, and new forms of treatment that CureLab is presently developing.
Dr Galloway is a cardiac surgeon and the Seymour Cohn Professor of Cardiothoracic Surgery at NYU Langone Health. He has directed the department's Cardiac Surgery Research and Clinical Trials program for more than 20 years and worked as Chair of the Department of Cardiothoracic Surgery for 15 years.
Novartis reports Leqvio demonstrates LDL-C lowering in Phase III trial
Hyundai Bioscience to conduct Phase 3 trial for high-risk COVID-19 patients
Bayer launches Phase II study for chronic kidney disease treatment
AstraZeneca's Calquence combo improves 1L CLL progression-free survival
Destiny Pharma's XF-73 nasal gel reduces antibiotic use in cardiac surgery patients